{"ticker": {"uuid": "1b784575-0970-4001-b3fe-566c9d387622", "symbol": "ONCY", "name": "Oncolytics Biotech Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer", "summary": "Oncolytics Biotech's shares rose following news of their plans to meet with the FDA regarding a registrational study for their drug pelareorep in metastatic pancreatic cancer, and positive interim data from a Phase 1/2 colorectal cancer trial. The company's strategy involves the ", "url": "https://www.moomoo.com/news/post/72868929/oncolytics-biotech-shares-rise-on-fda-meeting-plan-trial-progress?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T15:42:33", "published_display": "13 Jul 2026 15:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPM1RGUGJSVlVJbG9ycTV0T0xncXRIa1k3SXFmYy1tR1RkLU1xM2ozOXRldTEwLXNzcllUZGtaU240ZG5SUkY1cjVZYVRhbllvYTlfZ3FlajdMSWRnUVhaVU9odWlEdEF6a1JtYkd2NzJnUVVfMGc5OEd5U0phUnhmMXdoZDRKT0hCYW5uOXVyOWYzOEZrVEpETmZYb1VkckU?oc=5", "source_name": "Market source", "published_at": "2026-07-13T14:13:13+00:00", "published_display": "13 Jul 2026 14:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics (ONCY) Updates on REO 033 Clinical Study Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNVkdDaWlsYUpMN3BQVDdRdV9lQ0swTkNvd0xwYmNPX2VvNS1HYWEydkl3RjJOMnVHQnJ3SUdvYnRvdzVLUDRDZDY4Y0NFQWFEdmdHZkRia1J0X3d4cHZJMGItTEN5M0pXcU5zUkJTTGlIVENGQXJLZXJ0Z1Z4RXlzVXJkU3JFZDlLYnJaa0JDNm80RWNCUVhQY0JGNlp4UQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T14:04:05+00:00", "published_display": "13 Jul 2026 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cancer trial using pelareorep seeks FDA input on path to possible approval", "summary": "Oncolytics Biotech (ONCY) has reported significant clinical and regulatory progress for its REO 033 study, which evaluates pelareorep in patients with RAS-mutant MSS metastatic colorectal cancer. The company plans a Type D FDA meeting in early August 2026 to discuss adding a regi", "url": "https://www.stocktitan.net/news/ONCY/oncolytics-biotech-reports-fda-regulatory-milestone-and-strong-1uvo2f3w0yzd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:42:33", "published_display": "13 Jul 2026 12:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial", "summary": "Oncolytics Biotech is making strong clinical and regulatory progress with its REO 033 study for RAS-mutant, MSS metastatic colorectal cancer, with half of the planned clinical sites now activated and over 20 patients pre-identified. The company will hold a Type D meeting with the", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326226/0/en/oncolytics-biotech-reports-fda-regulatory-milestone-and-strong-clinical-progress-in-randomized-ras-mutant-mss-colorectal-cancer-trial.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T12:40:16", "published_display": "13 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE81TFRZU0o5TmZ6eTdQUGJ1UTN2bDRsOWtraFRfTGxwN2EzX25aX2xJRUZTeVB4WC1mal9QV01renpRcHFkYVU1SWtQd2s3ZlZNcUd6ZTU1UGx4NDQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:23:47+00:00", "published_display": "11 Jul 2026 00:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1% - What's Next?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNNklwbk1xSkpNVTQ5NVhFS0o5TWhjWUVYOF9hRlRNRG1yRlJ5emdUS1NNR1V2OVhBRzQ2RnViTE1ubmJIOV9Tc0Z2d0VFbk9vSENFX0tqYzlEdF93WkNxWmw2d0QzVHZ1NEE0RGRMalBjOFozS3NYWlVYRUt1R21aZUZCLXNFWXNJc1pUUUhpWk5PcHp2c0FLUldFSEZHUDYySzVJNWp0dzhvSnJQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T04:22:40+00:00", "published_display": "10 Jul 2026 04:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (ONCY) replaces Ernst & Young with Baker Tilly as 2026 auditor", "summary": "Oncolytics Biotech Inc. (ONCY) announced the replacement of Ernst & Young LLP with Baker Tilly US, LLP as its independent registered public accounting firm for the 2026 fiscal year due to corporate restructuring. The company confirmed that there were no disagreements with EY, and", "url": "https://www.stocktitan.net/sec-filings/ONCY/8-k-oncolytics-biotech-inc-reports-material-event-81bacbceec4d.html", "source_name": "Stock Titan", "published_at": "2026-07-09T07:39:38", "published_display": "09 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Oncolytics Biotech Inc. \u2013 NASDAQ:ONCY", "summary": "This article displays the \"Enterprise value to EBITDA forward\" metric for Oncolytics Biotech Inc. (NASDAQ: ONCY) on TradingView. It provides a historical overview of this specific financial ratio for the company, accessible through the platform's financial data section. The conte", "url": "https://www.tradingview.com/symbols/NASDAQ-ONCY/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T06:10:39", "published_display": "29 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Oncolytics Biotech Inc. \u2013 NASDAQ:ONCY", "summary": "This article focuses on the enterprise value to revenue forward metric for Oncolytics Biotech Inc. (NASDAQ: ONCY). It extracts financial information related to the company from TradingView, specifically highlighting its presence on the Nasdaq Stock Market. The content primarily c", "url": "https://www.tradingview.com/symbols/NASDAQ-ONCY/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T17:10:04", "published_display": "26 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Oncolytics Biotech Inc. (ONCY) stock, including analyst price targets and historical performance. It details the company's current stock price, market capitalization, earnings, and revenue, alongside a disclaimer that the information is not in", "url": "https://www.tradingview.com/symbols/NASDAQ-ONCY/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T14:09:27", "published_display": "26 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Oncolytics Biotech Inc. \u2013 NASDAQ:ONCY", "summary": "This article displays the \"Price to sales forward\" metric for Oncolytics Biotech Inc. (NASDAQ: ONCY). It appears to be a financial data point presented on a trading platform, indicating the company's valuation based on its projected sales. The article is sparse, primarily showing", "url": "https://www.tradingview.com/symbols/NASDAQ-ONCY/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:39:28", "published_display": "25 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech | 8-K: Current report", "summary": "This document is an 8-K filing by Oncolytics Biotech, a current report submitted to the Securities and Exchange Commission. The 8-K form is used by public companies to announce major events that shareholders should know about.", "url": "https://www.moomoo.com/news/notice/306868686/oncolytics-biotech-8-k-current-report", "source_name": "Moomoo", "published_at": "2026-06-21T14:40:21", "published_display": "21 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044", "summary": "Oncolytics Biotech Inc. announced that the USPTO has issued a new patent protecting its proprietary manufacturing process for pelareorep until 2044, enabling commercial-scale production. The company also has a method-of-use patent application that could extend protection to 2046 ", "url": "https://finance.yahoo.com/healthcare/articles/oncolytics-biotech-secures-u-patent-130000068.html", "source_name": "Market source", "published_at": "2026-06-19T01:39:28", "published_display": "19 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Oncolytics Biotech Inc (ONCY), focusing on its current valuation score, P/E ratio, and industry ranking. The company's valuation score is 7.92, placing it 187th out of 388 in the Biotechnology & Medical Research industry. It notes tha", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-oncy/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T07:10:13", "published_display": "18 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Inc (ONCY) Institutional Confidence", "summary": "This article analyzes the institutional confidence in Oncolytics Biotech Inc (ONCY), which currently holds a score of 3.00, placing it 193rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 80.02% quarter-over-quarter, r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-oncy/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:13", "published_display": "18 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae to Host Conference Call to Discuss First Qua", "summary": "Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) announced it will host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. ET. The call will cover a corporate update and financial results for the first quarter of 2024. Oncolytics is a clinical-stage biotechnolo", "url": "https://www.gurufocus.com/news/2421873/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and-recent-operational-highlights?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-18T03:10:13", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Gets US Patent for Pelareorep Manufacturing Process", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/oncolytics-gets-us-patent-pelareorep-141712930.html", "source_name": "MT Newswires", "published_at": "2026-06-16T14:17:12+00:00", "published_display": "16 Jun 2026 14:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Inc", "summary": "Oncolytics Biotech Inc. announced that the United States Patent and Trademark Office has issued a new patent covering its proprietary manufacturing process for pelareorep. This patent broadly protects key aspects of their manufacturing methods and is expected to provide intellect", "url": "http://www.baystreet.ca/stocksinplayarticles/47353/Oncolytics-Biotech-Inc47353", "source_name": "Baystreet.ca", "published_at": "2026-06-16T13:41:57", "published_display": "16 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process", "summary": "Oncolytics Biotech has announced that it has been granted a new US patent for its pelareorep manufacturing process. The article, while brief, indicates that this is a significant development for the company.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42O0FF:0-oncolytics-biotech-announces-new-us-patent-for-pelareorep-manufacturing-process/", "source_name": "TradingView", "published_at": "2026-06-16T13:39:39", "published_display": "16 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US patent shields Oncolytics' pelareorep manufacturing process into 2044", "summary": "Oncolytics Biotech has secured a new U.S. patent that protects its proprietary manufacturing process for pelareorep, an investigational immunotherapy, until 2044. This patent aims to ensure consistent commercial-scale production and is a significant addition to the company's inte", "url": "https://www.stocktitan.net/news/ONCY/oncolytics-biotech-secures-new-u-s-patent-protecting-commercial-asuxcpiks95k.html", "source_name": "Stock Titan", "published_at": "2026-06-16T12:39:39", "published_display": "16 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New pelareorep patent extends Oncolytics Biotech (Nasdaq: ONCY) IP to 2044", "summary": "Oncolytics Biotech Inc. announced a new U.S. patent that protects the commercial manufacturing process of its investigational immunotherapy, pelareorep, until 2044. The company also has a pending method-of-use patent application that, if granted, could extend protection to 2046, ", "url": "https://www.stocktitan.net/sec-filings/ONCY/8-k-oncolytics-biotech-inc-reports-material-event-1d7c16cf98a6.html", "source_name": "Stock Titan", "published_at": "2026-06-16T12:39:39", "published_display": "16 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY Stock Surged Today \u2013 Here\u2019s What Securing A Key Immunotherapy Patent Means For Oncolytics", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQWUpGd3ZseC0tMm9sUWFFei1udkplN3JuQWd4R0t1STZwYnV1dGhQUTYtUE1NRDJPVmFCWjFrc2luQW1WbTByV0p5YU9oWG8zNkE3M1hqZUZCZkJUcS1PZGVFdE5ueUVZZk1ETmI5bzZXc0NUQ0ZFRjloRFhTTTB0a1hmTXNZRldhTUNoWE1vOUwwcnhpV1k2ag?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics receives U.S. patent for pelareorep manufacturing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPaGt2YmVyWnRyeDV1MVJiWTJlOTAxdVVVQ1cxT20zaDdiOGlwdWtHajdWY1lMS01wYjBrU2RKR0FHYWFxQ2FRclpaOUpTZDctNEZmcEZQWktGNEhWN2ZqZWl5eGlWSVFFeExTSkdwZjI1WFNCeUhSam01SWRLdzUyNTRFTnpMbHlpajVvTm5qbjdkUHE5Q1hwSGRxQWlfSWV2Y290UVBxTE1jUExKd3cwQW8yOHRCUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY)", "summary": "LifeSci Capital reiterated a Buy rating for Enliven Therapeutics (ELVN) with a $60.00 price target, highlighting the company's Strong Buy consensus among analysts. Conversely, JonesTrading maintained a Hold rating on Oncolytics Biotech (ONCY), despite a Strong Buy consensus and a", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ONCY-Q/pressreleases/2446226/analysts-offer-insights-on-healthcare-companies-enliven-therapeutics-elvn-and-oncolytics-biotech-oncy/", "source_name": "The Globe and Mail", "published_at": "2026-06-12T19:08:38", "published_display": "12 Jun 2026 19:08", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JonesTrading Maintains Oncolytics Biotech(ONCY.US) With Hold Rating", "summary": "JonesTrading has reiterated its Hold rating on Oncolytics Biotech (ONCY.US). This action indicates that the firm is maintaining its current neutral stance on the company's stock.", "url": "https://www.moomoo.com/news/post/71410631/jonestrading-maintains-oncolytics-biotech-oncyus-with-hold-rating", "source_name": "Moomoo", "published_at": "2026-06-12T02:40:12", "published_display": "12 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY Stock Heads For Sixth Straight Session Of Gains \u2013 Lead Therapy Shines in Early Combination Treatment Study", "summary": "Oncolytics Biotech (ONCY) shares surged over 12% following promising preclinical data for its immunotherapy, Pelareorep. The therapy, when combined with RAS-targeting drugs, showed stronger anti-tumor effects, leading Oncolytics to plan expanded testing in pancreatic and colorect", "url": "https://stocktwits.com/news-articles/markets/equity/oncy-stock-gains-on-lead-therapy-promise/cZ0gw0DReHv", "source_name": "Stocktwits", "published_at": "2026-06-08T23:39:29", "published_display": "08 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY - Oncolytics Biotech Inc Stock Price and Quote", "summary": "This page provides detailed financial information and recent news for Oncolytics Biotech Inc (ONCY). It covers stock performance, key financial metrics, insider transactions, and a chronological list of company announcements and analyst ratings. The data indicates ONCY is a biote", "url": "https://finviz.com/stock?t=ONCY", "source_name": "Finviz", "published_at": "2026-06-08T07:10:15", "published_display": "08 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY Stock Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY)", "summary": "This page provides the stock chart and current price information for ONCOLYTICS BIOTECH INC (NASDAQ: ONCY). As of the close on June 8, 2026, the stock price was 0.84 USD. The page also features various trading tools and market data analysis options for users.", "url": "https://www.chartmill.com/stock/quote/ONCY/stock-chart", "source_name": "ChartMill", "published_at": "2026-06-06T06:39:29", "published_display": "06 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (NASDAQ: ONCY) grants director Rigby 30,000 options", "summary": "Oncolytics Biotech (NASDAQ: ONCY) director Jonathan Rigby was granted 30,000 stock options with an exercise price of $1.06 per share, matching the June 1, 2026 closing price. The options vest in three equal annual installments, beginning June 1, 2027, and expire on June 1, 2036. ", "url": "https://www.stocktitan.net/sec-filings/ONCY/form-4-oncolytics-biotech-inc-insider-trading-activity-f87de898ad7e.html", "source_name": "Stock Titan", "published_at": "2026-06-04T17:38:53", "published_display": "04 Jun 2026 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options at $1.06", "summary": "ONCOLYTICS BIOTECH INC director Wayne Pisano was granted 30,000 stock options at an exercise price of $1.06 per share, matching the closing price on June 1, 2026. These options will vest in three equal annual installments, with the first vesting on June 1, 2027, provided Pisano r", "url": "https://www.stocktitan.net/sec-filings/ONCY/form-4-oncolytics-biotech-inc-insider-trading-activity-047ee03ccc28.html", "source_name": "Stock Titan", "published_at": "2026-06-04T17:38:53", "published_display": "04 Jun 2026 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCOLYTICS (NASDAQ: ONCY) director awarded stock options on 30,000 shares", "summary": "ONCOLYTICS BIOTECH INC director Bernd R. Seizinger was granted stock options for 30,000 common shares with an exercise price of $1.06 per share, matching the closing price on June 1, 2026. These options expire on June 1, 2036, and vest in three equal annual installments starting ", "url": "https://www.stocktitan.net/sec-filings/ONCY/form-4-oncolytics-biotech-inc-insider-trading-activity-9cfac4bf388d.html", "source_name": "Stock Titan", "published_at": "2026-06-04T04:40:33", "published_display": "04 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Oncolytics Biotech (ONCY) Is Up 14.5% After New Pelareorep RAS-Tumor Immune Activation Data", "summary": "Oncolytics Biotech (ONCY) shares rose 14.5% following new data on its drug pelareorep, which showed enhanced anti-tumor activity and immune activation in RAS-driven cancers. This data reinforces pelareorep's potential in combination therapies and could influence future trial desi", "url": "https://www.sahmcapital.com/news/content/why-oncolytics-biotech-oncy-is-up-145-after-new-pelareorep-ras-tumor-immune-activation-data-2026-06-03", "source_name": "Sahm", "published_at": "2026-06-04T04:40:33", "published_display": "04 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxONUpKUEZFa1RaZ204S0ZscmxlNUwtWldhQlU2Zl9adzdfM1lGTjVYSFh0SHRfRVlVMmZuQ3Y0OVZDbEVGN0N1YkRyU0hIX1YyWFRPU1N2MkxtRVVuU3p6TnhZVkhaaE1JeEFpV3FXa196V3pHQ1RfU1JVVmRGR0JzdFFrVXRPa09tZXZQSGVCNjQ4NEx0REtOZWMtWXB5NEREcHFGZjV4NHh3LVA5?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (ONCY) COO discloses 500,000-share stock option holding", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxON0xyLU5EdUc3N1B5MkV5ZkZ5blJKQ1Z6SjdSbmVHbFBvdjVQS29tLUdFN0FiQjgtWkJxcVFRNExhUWJwR3R2ci1QWUh0SmZQUG5jZXVoT2Y0NTJTcTRzNFRhUUIxLVo0SWhtOUhxT0dXM1lSVW53bS1SckNvY3JtcF9HRjh3dHFabUNKRmROYTBzUndFcS1tNWNiaW1sM2FCeHI4RkJEajUyYU1IYTJQclg1blFNLXhlTC1MYm5HYTNTWEVmSFZRNE85bw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCOLYTICS (ONCY) CFO receives 260,000 stock options at $1.06 exercise price", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNQzhOcXp3RkF6QU1RTmV2YWFhaWJYLXVkVm9sNXJYTUZzVG05ZG5oX2UzVGhVeXQ1M2FBaTYwcGlFeXcyTklFSk9DT3JWcjVfSUNQZnNGdldoeWt4dlY2d2ZkdDhGUU5TNXE5ZEN1MHlYdjktMjBrMkt0bk1MWUp1UVB3b056cDJlRk5rc2JUb3BFbnJVTUJXSmVwNFZ0emdQa0tlTlNzWlhrQWp2eG1sU3hGOFNzbTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Names Steve Glover to Board; Promotes John McAdory to COO", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oncolytics-biotech-names-steve-glover-132045691.html", "source_name": "MT Newswires", "published_at": "2026-06-02T13:20:45+00:00", "published_display": "02 Jun 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Announces Positive Initial Preclinical", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygJBVV95cUxPYi1TSjNTMWRLOE9MdVQ3dmgtOU13aTNndHJONjRkTFU3R2QzNmNrVFB1WGFYNVZWUG1jSl9BU3JWR19ZWC1OOXY5Zm9JSm5pdTVYN2VvSWxsb1FRSzdDRmJtcUpEb0lkdlFrUVBPSEdJT24xbzZtS0N3aTJ1MFdRUUZNRUhEaU01VVZkRnFpcnRwUWw4a1JFOFpxV1B1Y0JJOGZ1X0tkZ1drWUhZTGJoVnZBeGY0RFd5YV9Qd2daZEw3SGd5NEtSLVBoNFNGOTBmZkZheXMtOER4WEtZWHVkSmQwWWZDYmVOYW41c3dDampjMUlIYkptTkFiVUMwczhpRjhva2lxMTVHaE1sdHA5alZMazRCWS1ueloxWHdQQWR0bGRTd2R6VE5YUG5wdGRxVG1Hdld1QlhFbTFXam96VThnbktmYWRKSUE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Oncolytics Biotech\u2019s Pelareorep Data Reshapes Colorectal Cancer And Investor Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPMW5jeHZYZmI0ellJUGdiS0tRWDRFZXl4YldaYzVIQXdKcVB2NUxDRkxDa1g0RUVGNXpEdGJPcUJRbmxDeDg2d0wtb3JkSkZxcDB3M201cnJwMU9YaWV3dGd1LU9jRktxemxsYUY0U19Nc2F4bEl1bzRJeV9MRlV4WnVmYWc4TkVHd2szZkZycmE3SDRpM24tLUxZQlRkODhrb25NT3llLVVMMVRDU2hveWVpUDZsaXRUMm93V2VtNkZfRW42blFkdkRRN0JKTzRxUDdabVg0OVVfYmJFZ0RkaDVDS05acGtHUS1yeXU5aTdPOFhnRVFn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Oncolytics Biotech (ONCY) Price Reset Creating A Long Term Opportunity?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics shifts to Nevada as San Diego becomes new headquarters", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQYVQ0aEV3c2R6VjhTY01pY0dxdVZLSzNYTzZkVVI4NENBV0dBb3UzMjI4bnM3dGxYQS1NMWJjZW0tWlJHWUpPUVhJbEszMWZPS0Z0alJyQUIyVWNQSkRsQ2Ewc01say1VOWNMTmkwcWxFV09LcXVHbWMxOFROTHkzZWlvQnU4OWUybVZzQi1OMDU1NTBUZkdJMGw4aF83eDNNZTd4eU5fRmtOV25JMzQ4dnhaVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u2019s Nevada Move Resets Capital Access And Dilution Trade Off", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPUDMxcjdCY2ZTbGQxOWxVU21DZHpaY3VrcjBpNUNPR2dTLWVUYUROdmI2a1ZocWR1VzBZRW5LbC1MVElOc1VBNG96ODMyMUxmbnZfQkRwWDRHcHl4SnE3c0pJR1kzZXFMbUprWlcxb0dMaHROUmxzYUdWcGYtc2tPMnBiMWt3UGFjUV9kT0p4TnZKNG9uME1la3Q2a2V1M0VJWi1Ocw?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Completes Domicile Change to the United States", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQWmhHb2IteDRCYmNUeS1hTHBLT3F5S3hneGtLRlBlNk85WG1XWTRLb3ZtRFlZbnFUMWs1Nmc0dzd4bzdOWmtMeERIVFpkbGFhNGNTcjc2dzlPMnZPaTZjVENES1VDaUlSdHFHOU0xOV81MklBa1dWQXpZY1dlYmxzQk94b21LbEZtN3MyLWpCM2hQQk1VQWdpYnRPMkFUTDVfNkNmcnUxX1Nud1VHM0Z6NU5CVmNCc2xxeFB2TTJMSGpyZU9xWGFNUXBzMUxTZHhFMnlJ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Oncolytics Biotech (ONCY) Valuation Check After Recent Share Price Momentum And Conflicting Signals", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Oncolytics Biotech (ONCY) Valuation After FDA Fast Track Designation For Pelareorep", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPRi1rVF9pMDFfdmtjZWM2aFdKcVZlVFRRN0FtLUV0azczTnpYYngwdlp0RjEzcW5PdjJPVU1vazVaMWxOV3JCQnBPQ1RRS29ocDlFeDI5NEpuUERKTFZLOUZlVllzRy0wQ1NoQWVpalVOaHVJNlFfUV9ud3l4SUZxVVVpeWNvNWxXSmRZSE9EZjhPY00?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant Colorectal Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPdWdPQVNCc1NMSGFuTVc1Vkp6ZEZ0Rzk3MUJRSldEVlBLWGtoc1JnNkRzVTI2NUhaemNlOXVMX0FmRHZ6MHZSckUyekJPak9oTlg2dWtSUlhQWUo1Q1QyMExWWnpsXzZQZzN5MFJqNC1Qa2xxcW5hTEZpbmd3QkZ4Wmdn?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxNQ3ZjaVVzdUJzUGxqWGU1T05jYjhrNGFQaXhtZjNqSjJ5SUhkbTA3U2gyM3dvMTRtbXBKdDV1Q2Z0ZFhiTGRQR3dibzNWZjJUbC1lN1FIT1R3WmltUW5ubl9YSXdKNzdXUFJPUEdLd3lnUjJfZEhDcWJLTzhBUkNLMDVzaWZpWVJDSXpOSzlWTjhjakpWWDRTZkpLWXRwc1U3TDhpNW40c0ZuVW1Nd1FIQ0ZBWE9QRlpZODRYNktnR2lLOEktT3FCMko0VldHZVZOekNlOFpORmZoSlROVmdNYzF4cVBVd05Sb0l1eEZlYlk0dTBydzdKM2VpUzRLTmJKaTZLR0FCNldXVWU0Z3c?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNejdwSTBZUVc5WEQ0QVlid1FQRG4yNE82X1ZiTXctTDJkSW5DYjdxME1adTBmWFpidkN6Z0NfY1BlUXE0Q3N1VkRyUk5nbWVPVklLWHRDVm1vc2pPcWlPSkl2eWp6Tk0zQzhxR0JxRnVzbC1TdGczaC1PTU5lRFFZTUF6TQ?oc=5", "source_name": "Market source", "published_at": "2025-12-03T08:00:00+00:00", "published_display": "03 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Oncolytics Biotech (NASDAQ:ONCY) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-03T07:00:00+00:00", "published_display": "03 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Announces Voluntary Delisting from the Toronto Stock Exchange", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQa3RkQ2hIUU10RWVUOEhfOHV0Ykh3ZF9MNGE1TWJUSzN2Ukt4Wi1FbGpWX0VPTWp1NzNweUd3Y3YzcDgydTFjLTBZMkk4NjJ4YUNkb21mUTY2bjJFOEJyYkhoUmR0SUpUTlBQQ0lHUDB6N05LTVl3VnJtRVBlSjRvU2VZcTktUVQ4b0ZKczBUY2VBZzBFNk5sQVlBam9tZkRmXzJkQlFaQkZLcXRDa2xEeW5adnhjQmJPd0Z4OENWN2Z4TUJrWF9EV2FnNVRCOUVZdVE?oc=5", "source_name": "PR Newswire", "published_at": "2025-08-08T07:00:00+00:00", "published_display": "08 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer", "summary": "Oncolytics Biotech's shares rose following news of their plans to meet with the FDA regarding a registrational study for their drug pelareorep in metastatic pancreatic cancer, and positive interim data from a Phase 1/2 colorectal cancer trial. The company's strategy involves the ", "url": "https://www.moomoo.com/news/post/72868929/oncolytics-biotech-shares-rise-on-fda-meeting-plan-trial-progress?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T15:42:33", "published_display": "13 Jul 2026 15:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPM1RGUGJSVlVJbG9ycTV0T0xncXRIa1k3SXFmYy1tR1RkLU1xM2ozOXRldTEwLXNzcllUZGtaU240ZG5SUkY1cjVZYVRhbllvYTlfZ3FlajdMSWRnUVhaVU9odWlEdEF6a1JtYkd2NzJnUVVfMGc5OEd5U0phUnhmMXdoZDRKT0hCYW5uOXVyOWYzOEZrVEpETmZYb1VkckU?oc=5", "source_name": "Market source", "published_at": "2026-07-13T14:13:13+00:00", "published_display": "13 Jul 2026 14:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics (ONCY) Updates on REO 033 Clinical Study Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNVkdDaWlsYUpMN3BQVDdRdV9lQ0swTkNvd0xwYmNPX2VvNS1HYWEydkl3RjJOMnVHQnJ3SUdvYnRvdzVLUDRDZDY4Y0NFQWFEdmdHZkRia1J0X3d4cHZJMGItTEN5M0pXcU5zUkJTTGlIVENGQXJLZXJ0Z1Z4RXlzVXJkU3JFZDlLYnJaa0JDNm80RWNCUVhQY0JGNlp4UQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T14:04:05+00:00", "published_display": "13 Jul 2026 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer trial using pelareorep seeks FDA input on path to possible approval", "summary": "Oncolytics Biotech (ONCY) has reported significant clinical and regulatory progress for its REO 033 study, which evaluates pelareorep in patients with RAS-mutant MSS metastatic colorectal cancer. The company plans a Type D FDA meeting in early August 2026 to discuss adding a regi", "url": "https://www.stocktitan.net/news/ONCY/oncolytics-biotech-reports-fda-regulatory-milestone-and-strong-1uvo2f3w0yzd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:42:33", "published_display": "13 Jul 2026 12:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial", "summary": "Oncolytics Biotech is making strong clinical and regulatory progress with its REO 033 study for RAS-mutant, MSS metastatic colorectal cancer, with half of the planned clinical sites now activated and over 20 patients pre-identified. The company will hold a Type D meeting with the", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326226/0/en/oncolytics-biotech-reports-fda-regulatory-milestone-and-strong-clinical-progress-in-randomized-ras-mutant-mss-colorectal-cancer-trial.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T12:40:16", "published_display": "13 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE81TFRZU0o5TmZ6eTdQUGJ1UTN2bDRsOWtraFRfTGxwN2EzX25aX2xJRUZTeVB4WC1mal9QV01renpRcHFkYVU1SWtQd2s3ZlZNcUd6ZTU1UGx4NDQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:23:47+00:00", "published_display": "11 Jul 2026 00:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1% - What's Next?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNNklwbk1xSkpNVTQ5NVhFS0o5TWhjWUVYOF9hRlRNRG1yRlJ5emdUS1NNR1V2OVhBRzQ2RnViTE1ubmJIOV9Tc0Z2d0VFbk9vSENFX0tqYzlEdF93WkNxWmw2d0QzVHZ1NEE0RGRMalBjOFozS3NYWlVYRUt1R21aZUZCLXNFWXNJc1pUUUhpWk5PcHp2c0FLUldFSEZHUDYySzVJNWp0dzhvSnJQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T04:22:40+00:00", "published_display": "10 Jul 2026 04:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (ONCY) replaces Ernst & Young with Baker Tilly as 2026 auditor", "summary": "Oncolytics Biotech Inc. (ONCY) announced the replacement of Ernst & Young LLP with Baker Tilly US, LLP as its independent registered public accounting firm for the 2026 fiscal year due to corporate restructuring. The company confirmed that there were no disagreements with EY, and", "url": "https://www.stocktitan.net/sec-filings/ONCY/8-k-oncolytics-biotech-inc-reports-material-event-81bacbceec4d.html", "source_name": "Stock Titan", "published_at": "2026-07-09T07:39:38", "published_display": "09 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Oncolytics Biotech Inc. \u2013 NASDAQ:ONCY", "summary": "This article displays the \"Enterprise value to EBITDA forward\" metric for Oncolytics Biotech Inc. (NASDAQ: ONCY) on TradingView. It provides a historical overview of this specific financial ratio for the company, accessible through the platform's financial data section. The conte", "url": "https://www.tradingview.com/symbols/NASDAQ-ONCY/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T06:10:39", "published_display": "29 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Oncolytics Biotech Inc. \u2013 NASDAQ:ONCY", "summary": "This article focuses on the enterprise value to revenue forward metric for Oncolytics Biotech Inc. (NASDAQ: ONCY). It extracts financial information related to the company from TradingView, specifically highlighting its presence on the Nasdaq Stock Market. The content primarily c", "url": "https://www.tradingview.com/symbols/NASDAQ-ONCY/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T17:10:04", "published_display": "26 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Oncolytics Biotech Inc. (ONCY) stock, including analyst price targets and historical performance. It details the company's current stock price, market capitalization, earnings, and revenue, alongside a disclaimer that the information is not in", "url": "https://www.tradingview.com/symbols/NASDAQ-ONCY/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T14:09:27", "published_display": "26 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Oncolytics Biotech Inc. \u2013 NASDAQ:ONCY", "summary": "This article displays the \"Price to sales forward\" metric for Oncolytics Biotech Inc. (NASDAQ: ONCY). It appears to be a financial data point presented on a trading platform, indicating the company's valuation based on its projected sales. The article is sparse, primarily showing", "url": "https://www.tradingview.com/symbols/NASDAQ-ONCY/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:39:28", "published_display": "25 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech | 8-K: Current report", "summary": "This document is an 8-K filing by Oncolytics Biotech, a current report submitted to the Securities and Exchange Commission. The 8-K form is used by public companies to announce major events that shareholders should know about.", "url": "https://www.moomoo.com/news/notice/306868686/oncolytics-biotech-8-k-current-report", "source_name": "Moomoo", "published_at": "2026-06-21T14:40:21", "published_display": "21 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044", "summary": "Oncolytics Biotech Inc. announced that the USPTO has issued a new patent protecting its proprietary manufacturing process for pelareorep until 2044, enabling commercial-scale production. The company also has a method-of-use patent application that could extend protection to 2046 ", "url": "https://finance.yahoo.com/healthcare/articles/oncolytics-biotech-secures-u-patent-130000068.html", "source_name": "Market source", "published_at": "2026-06-19T01:39:28", "published_display": "19 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Oncolytics Biotech Inc (ONCY), focusing on its current valuation score, P/E ratio, and industry ranking. The company's valuation score is 7.92, placing it 187th out of 388 in the Biotechnology & Medical Research industry. It notes tha", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-oncy/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T07:10:13", "published_display": "18 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Inc (ONCY) Institutional Confidence", "summary": "This article analyzes the institutional confidence in Oncolytics Biotech Inc (ONCY), which currently holds a score of 3.00, placing it 193rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 80.02% quarter-over-quarter, r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-oncy/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:13", "published_display": "18 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae to Host Conference Call to Discuss First Qua", "summary": "Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) announced it will host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. ET. The call will cover a corporate update and financial results for the first quarter of 2024. Oncolytics is a clinical-stage biotechnolo", "url": "https://www.gurufocus.com/news/2421873/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and-recent-operational-highlights?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-18T03:10:13", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Gets US Patent for Pelareorep Manufacturing Process", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/oncolytics-gets-us-patent-pelareorep-141712930.html", "source_name": "MT Newswires", "published_at": "2026-06-16T14:17:12+00:00", "published_display": "16 Jun 2026 14:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Inc", "summary": "Oncolytics Biotech Inc. announced that the United States Patent and Trademark Office has issued a new patent covering its proprietary manufacturing process for pelareorep. This patent broadly protects key aspects of their manufacturing methods and is expected to provide intellect", "url": "http://www.baystreet.ca/stocksinplayarticles/47353/Oncolytics-Biotech-Inc47353", "source_name": "Baystreet.ca", "published_at": "2026-06-16T13:41:57", "published_display": "16 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process", "summary": "Oncolytics Biotech has announced that it has been granted a new US patent for its pelareorep manufacturing process. The article, while brief, indicates that this is a significant development for the company.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42O0FF:0-oncolytics-biotech-announces-new-us-patent-for-pelareorep-manufacturing-process/", "source_name": "TradingView", "published_at": "2026-06-16T13:39:39", "published_display": "16 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US patent shields Oncolytics' pelareorep manufacturing process into 2044", "summary": "Oncolytics Biotech has secured a new U.S. patent that protects its proprietary manufacturing process for pelareorep, an investigational immunotherapy, until 2044. This patent aims to ensure consistent commercial-scale production and is a significant addition to the company's inte", "url": "https://www.stocktitan.net/news/ONCY/oncolytics-biotech-secures-new-u-s-patent-protecting-commercial-asuxcpiks95k.html", "source_name": "Stock Titan", "published_at": "2026-06-16T12:39:39", "published_display": "16 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New pelareorep patent extends Oncolytics Biotech (Nasdaq: ONCY) IP to 2044", "summary": "Oncolytics Biotech Inc. announced a new U.S. patent that protects the commercial manufacturing process of its investigational immunotherapy, pelareorep, until 2044. The company also has a pending method-of-use patent application that, if granted, could extend protection to 2046, ", "url": "https://www.stocktitan.net/sec-filings/ONCY/8-k-oncolytics-biotech-inc-reports-material-event-1d7c16cf98a6.html", "source_name": "Stock Titan", "published_at": "2026-06-16T12:39:39", "published_display": "16 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY Stock Surged Today \u2013 Here\u2019s What Securing A Key Immunotherapy Patent Means For Oncolytics", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQWUpGd3ZseC0tMm9sUWFFei1udkplN3JuQWd4R0t1STZwYnV1dGhQUTYtUE1NRDJPVmFCWjFrc2luQW1WbTByV0p5YU9oWG8zNkE3M1hqZUZCZkJUcS1PZGVFdE5ueUVZZk1ETmI5bzZXc0NUQ0ZFRjloRFhTTTB0a1hmTXNZRldhTUNoWE1vOUwwcnhpV1k2ag?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics receives U.S. patent for pelareorep manufacturing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPaGt2YmVyWnRyeDV1MVJiWTJlOTAxdVVVQ1cxT20zaDdiOGlwdWtHajdWY1lMS01wYjBrU2RKR0FHYWFxQ2FRclpaOUpTZDctNEZmcEZQWktGNEhWN2ZqZWl5eGlWSVFFeExTSkdwZjI1WFNCeUhSam01SWRLdzUyNTRFTnpMbHlpajVvTm5qbjdkUHE5Q1hwSGRxQWlfSWV2Y290UVBxTE1jUExKd3cwQW8yOHRCUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY)", "summary": "LifeSci Capital reiterated a Buy rating for Enliven Therapeutics (ELVN) with a $60.00 price target, highlighting the company's Strong Buy consensus among analysts. Conversely, JonesTrading maintained a Hold rating on Oncolytics Biotech (ONCY), despite a Strong Buy consensus and a", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ONCY-Q/pressreleases/2446226/analysts-offer-insights-on-healthcare-companies-enliven-therapeutics-elvn-and-oncolytics-biotech-oncy/", "source_name": "The Globe and Mail", "published_at": "2026-06-12T19:08:38", "published_display": "12 Jun 2026 19:08", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JonesTrading Maintains Oncolytics Biotech(ONCY.US) With Hold Rating", "summary": "JonesTrading has reiterated its Hold rating on Oncolytics Biotech (ONCY.US). This action indicates that the firm is maintaining its current neutral stance on the company's stock.", "url": "https://www.moomoo.com/news/post/71410631/jonestrading-maintains-oncolytics-biotech-oncyus-with-hold-rating", "source_name": "Moomoo", "published_at": "2026-06-12T02:40:12", "published_display": "12 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY Stock Heads For Sixth Straight Session Of Gains \u2013 Lead Therapy Shines in Early Combination Treatment Study", "summary": "Oncolytics Biotech (ONCY) shares surged over 12% following promising preclinical data for its immunotherapy, Pelareorep. The therapy, when combined with RAS-targeting drugs, showed stronger anti-tumor effects, leading Oncolytics to plan expanded testing in pancreatic and colorect", "url": "https://stocktwits.com/news-articles/markets/equity/oncy-stock-gains-on-lead-therapy-promise/cZ0gw0DReHv", "source_name": "Stocktwits", "published_at": "2026-06-08T23:39:29", "published_display": "08 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY - Oncolytics Biotech Inc Stock Price and Quote", "summary": "This page provides detailed financial information and recent news for Oncolytics Biotech Inc (ONCY). It covers stock performance, key financial metrics, insider transactions, and a chronological list of company announcements and analyst ratings. The data indicates ONCY is a biote", "url": "https://finviz.com/stock?t=ONCY", "source_name": "Finviz", "published_at": "2026-06-08T07:10:15", "published_display": "08 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCY Stock Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY)", "summary": "This page provides the stock chart and current price information for ONCOLYTICS BIOTECH INC (NASDAQ: ONCY). As of the close on June 8, 2026, the stock price was 0.84 USD. The page also features various trading tools and market data analysis options for users.", "url": "https://www.chartmill.com/stock/quote/ONCY/stock-chart", "source_name": "ChartMill", "published_at": "2026-06-06T06:39:29", "published_display": "06 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (NASDAQ: ONCY) grants director Rigby 30,000 options", "summary": "Oncolytics Biotech (NASDAQ: ONCY) director Jonathan Rigby was granted 30,000 stock options with an exercise price of $1.06 per share, matching the June 1, 2026 closing price. The options vest in three equal annual installments, beginning June 1, 2027, and expire on June 1, 2036. ", "url": "https://www.stocktitan.net/sec-filings/ONCY/form-4-oncolytics-biotech-inc-insider-trading-activity-f87de898ad7e.html", "source_name": "Stock Titan", "published_at": "2026-06-04T17:38:53", "published_display": "04 Jun 2026 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options at $1.06", "summary": "ONCOLYTICS BIOTECH INC director Wayne Pisano was granted 30,000 stock options at an exercise price of $1.06 per share, matching the closing price on June 1, 2026. These options will vest in three equal annual installments, with the first vesting on June 1, 2027, provided Pisano r", "url": "https://www.stocktitan.net/sec-filings/ONCY/form-4-oncolytics-biotech-inc-insider-trading-activity-047ee03ccc28.html", "source_name": "Stock Titan", "published_at": "2026-06-04T17:38:53", "published_display": "04 Jun 2026 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCOLYTICS (NASDAQ: ONCY) director awarded stock options on 30,000 shares", "summary": "ONCOLYTICS BIOTECH INC director Bernd R. Seizinger was granted stock options for 30,000 common shares with an exercise price of $1.06 per share, matching the closing price on June 1, 2026. These options expire on June 1, 2036, and vest in three equal annual installments starting ", "url": "https://www.stocktitan.net/sec-filings/ONCY/form-4-oncolytics-biotech-inc-insider-trading-activity-9cfac4bf388d.html", "source_name": "Stock Titan", "published_at": "2026-06-04T04:40:33", "published_display": "04 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Oncolytics Biotech (ONCY) Is Up 14.5% After New Pelareorep RAS-Tumor Immune Activation Data", "summary": "Oncolytics Biotech (ONCY) shares rose 14.5% following new data on its drug pelareorep, which showed enhanced anti-tumor activity and immune activation in RAS-driven cancers. This data reinforces pelareorep's potential in combination therapies and could influence future trial desi", "url": "https://www.sahmcapital.com/news/content/why-oncolytics-biotech-oncy-is-up-145-after-new-pelareorep-ras-tumor-immune-activation-data-2026-06-03", "source_name": "Sahm", "published_at": "2026-06-04T04:40:33", "published_display": "04 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxONUpKUEZFa1RaZ204S0ZscmxlNUwtWldhQlU2Zl9adzdfM1lGTjVYSFh0SHRfRVlVMmZuQ3Y0OVZDbEVGN0N1YkRyU0hIX1YyWFRPU1N2MkxtRVVuU3p6TnhZVkhaaE1JeEFpV3FXa196V3pHQ1RfU1JVVmRGR0JzdFFrVXRPa09tZXZQSGVCNjQ4NEx0REtOZWMtWXB5NEREcHFGZjV4NHh3LVA5?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (ONCY) COO discloses 500,000-share stock option holding", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxON0xyLU5EdUc3N1B5MkV5ZkZ5blJKQ1Z6SjdSbmVHbFBvdjVQS29tLUdFN0FiQjgtWkJxcVFRNExhUWJwR3R2ci1QWUh0SmZQUG5jZXVoT2Y0NTJTcTRzNFRhUUIxLVo0SWhtOUhxT0dXM1lSVW53bS1SckNvY3JtcF9HRjh3dHFabUNKRmROYTBzUndFcS1tNWNiaW1sM2FCeHI4RkJEajUyYU1IYTJQclg1blFNLXhlTC1MYm5HYTNTWEVmSFZRNE85bw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ONCOLYTICS (ONCY) CFO receives 260,000 stock options at $1.06 exercise price", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNQzhOcXp3RkF6QU1RTmV2YWFhaWJYLXVkVm9sNXJYTUZzVG05ZG5oX2UzVGhVeXQ1M2FBaTYwcGlFeXcyTklFSk9DT3JWcjVfSUNQZnNGdldoeWt4dlY2d2ZkdDhGUU5TNXE5ZEN1MHlYdjktMjBrMkt0bk1MWUp1UVB3b056cDJlRk5rc2JUb3BFbnJVTUJXSmVwNFZ0emdQa0tlTlNzWlhrQWp2eG1sU3hGOFNzbTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech Names Steve Glover to Board; Promotes John McAdory to COO", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oncolytics-biotech-names-steve-glover-132045691.html", "source_name": "MT Newswires", "published_at": "2026-06-02T13:20:45+00:00", "published_display": "02 Jun 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Announces Positive Initial Preclinical", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygJBVV95cUxPYi1TSjNTMWRLOE9MdVQ3dmgtOU13aTNndHJONjRkTFU3R2QzNmNrVFB1WGFYNVZWUG1jSl9BU3JWR19ZWC1OOXY5Zm9JSm5pdTVYN2VvSWxsb1FRSzdDRmJtcUpEb0lkdlFrUVBPSEdJT24xbzZtS0N3aTJ1MFdRUUZNRUhEaU01VVZkRnFpcnRwUWw4a1JFOFpxV1B1Y0JJOGZ1X0tkZ1drWUhZTGJoVnZBeGY0RFd5YV9Qd2daZEw3SGd5NEtSLVBoNFNGOTBmZkZheXMtOER4WEtZWHVkSmQwWWZDYmVOYW41c3dDampjMUlIYkptTkFiVUMwczhpRjhva2lxMTVHaE1sdHA5alZMazRCWS1ueloxWHdQQWR0bGRTd2R6VE5YUG5wdGRxVG1Hdld1QlhFbTFXam96VThnbktmYWRKSUE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u2019s Pelareorep Data Reshapes Colorectal Cancer And Investor Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPMW5jeHZYZmI0ellJUGdiS0tRWDRFZXl4YldaYzVIQXdKcVB2NUxDRkxDa1g0RUVGNXpEdGJPcUJRbmxDeDg2d0wtb3JkSkZxcDB3M201cnJwMU9YaWV3dGd1LU9jRktxemxsYUY0U19Nc2F4bEl1bzRJeV9MRlV4WnVmYWc4TkVHd2szZkZycmE3SDRpM24tLUxZQlRkODhrb25NT3llLVVMMVRDU2hveWVpUDZsaXRUMm93V2VtNkZfRW42blFkdkRRN0JKTzRxUDdabVg0OVVfYmJFZ0RkaDVDS05acGtHUS1yeXU5aTdPOFhnRVFn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Oncolytics Biotech (ONCY) Price Reset Creating A Long Term Opportunity?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics shifts to Nevada as San Diego becomes new headquarters", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQYVQ0aEV3c2R6VjhTY01pY0dxdVZLSzNYTzZkVVI4NENBV0dBb3UzMjI4bnM3dGxYQS1NMWJjZW0tWlJHWUpPUVhJbEszMWZPS0Z0alJyQUIyVWNQSkRsQ2Ewc01say1VOWNMTmkwcWxFV09LcXVHbWMxOFROTHkzZWlvQnU4OWUybVZzQi1OMDU1NTBUZkdJMGw4aF83eDNNZTd4eU5fRmtOV25JMzQ4dnhaVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u2019s Nevada Move Resets Capital Access And Dilution Trade Off", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPUDMxcjdCY2ZTbGQxOWxVU21DZHpaY3VrcjBpNUNPR2dTLWVUYUROdmI2a1ZocWR1VzBZRW5LbC1MVElOc1VBNG96ODMyMUxmbnZfQkRwWDRHcHl4SnE3c0pJR1kzZXFMbUprWlcxb0dMaHROUmxzYUdWcGYtc2tPMnBiMWt3UGFjUV9kT0p4TnZKNG9uME1la3Q2a2V1M0VJWi1Ocw?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Completes Domicile Change to the United States", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQWmhHb2IteDRCYmNUeS1hTHBLT3F5S3hneGtLRlBlNk85WG1XWTRLb3ZtRFlZbnFUMWs1Nmc0dzd4bzdOWmtMeERIVFpkbGFhNGNTcjc2dzlPMnZPaTZjVENES1VDaUlSdHFHOU0xOV81MklBa1dWQXpZY1dlYmxzQk94b21LbEZtN3MyLWpCM2hQQk1VQWdpYnRPMkFUTDVfNkNmcnUxX1Nud1VHM0Z6NU5CVmNCc2xxeFB2TTJMSGpyZU9xWGFNUXBzMUxTZHhFMnlJ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (ONCY) Valuation Check After Recent Share Price Momentum And Conflicting Signals", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Oncolytics Biotech (ONCY) Valuation After FDA Fast Track Designation For Pelareorep", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPRi1rVF9pMDFfdmtjZWM2aFdKcVZlVFRRN0FtLUV0azczTnpYYngwdlp0RjEzcW5PdjJPVU1vazVaMWxOV3JCQnBPQ1RRS29ocDlFeDI5NEpuUERKTFZLOUZlVllzRy0wQ1NoQWVpalVOaHVJNlFfUV9ud3l4SUZxVVVpeWNvNWxXSmRZSE9EZjhPY00?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant Colorectal Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPdWdPQVNCc1NMSGFuTVc1Vkp6ZEZ0Rzk3MUJRSldEVlBLWGtoc1JnNkRzVTI2NUhaemNlOXVMX0FmRHZ6MHZSckUyekJPak9oTlg2dWtSUlhQWUo1Q1QyMExWWnpsXzZQZzN5MFJqNC1Qa2xxcW5hTEZpbmd3QkZ4Wmdn?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxNQ3ZjaVVzdUJzUGxqWGU1T05jYjhrNGFQaXhtZjNqSjJ5SUhkbTA3U2gyM3dvMTRtbXBKdDV1Q2Z0ZFhiTGRQR3dibzNWZjJUbC1lN1FIT1R3WmltUW5ubl9YSXdKNzdXUFJPUEdLd3lnUjJfZEhDcWJLTzhBUkNLMDVzaWZpWVJDSXpOSzlWTjhjakpWWDRTZkpLWXRwc1U3TDhpNW40c0ZuVW1Nd1FIQ0ZBWE9QRlpZODRYNktnR2lLOEktT3FCMko0VldHZVZOekNlOFpORmZoSlROVmdNYzF4cVBVd05Sb0l1eEZlYlk0dTBydzdKM2VpUzRLTmJKaTZLR0FCNldXVWU0Z3c?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNejdwSTBZUVc5WEQ0QVlid1FQRG4yNE82X1ZiTXctTDJkSW5DYjdxME1adTBmWFpidkN6Z0NfY1BlUXE0Q3N1VkRyUk5nbWVPVklLWHRDVm1vc2pPcWlPSkl2eWp6Tk0zQzhxR0JxRnVzbC1TdGczaC1PTU5lRFFZTUF6TQ?oc=5", "source_name": "Market source", "published_at": "2025-12-03T08:00:00+00:00", "published_display": "03 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Oncolytics Biotech (NASDAQ:ONCY) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNV29RLXA2MmJBbWl4dkE1TEJwRXU2WHFGbjVHUDVEaHVyQmdMQldQdDlDV2lZNzZkempOeHIyQy1GMUJDM0tiNmU2bVJ4NVpIamNfQmc1Y1hvT3hORkVLbndGUWdRRlY2eWsyRk0taTJ3OWo2VGlOUXh2Z1JPN2o0YWtxZ0QwQmtYUjBVdENabVRCeEI0LTJvSTIzWXlhcWZIQktsOFJkbjR4RnhGdUVzVGxZZG4zMV9VWjFoSHV1cHlvdlFIZldEekxwZjBuM0Vjd184QUdfVHdLbEQzWUpPdkM2OG9zZjTSAewBQVVfeXFMUHJWc1FFTEZSay1qWVJubG9GdHk4Yl9LZ19nSW1VeVBPdW9aNzhTUnNQb2pUcXl5YlFpLTBtQ0ZwQWM2bTdxVmZET2w4eDJiZFd4RVF6U0FrcXNvS1RST1VlU0hZRGdOTXRPeEFreGdONUdCNWVwazlady1fdmlWaXk2WG0wYXowVVFKNTg0MlUxWWc0c1N4WUxLVEtNaS1BcHhDN0FnSmZJXzRyRlM1dHdmZDE0aDFjdm81UFBCQ2NWSktjUGdLYUNXVkdqX2l5bWJobGE1MW5vQjhmei0yNm1mRVQyajFPTGhJc20?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-03T07:00:00+00:00", "published_display": "03 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncolytics Biotech\u00ae Announces Voluntary Delisting from the Toronto Stock Exchange", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQa3RkQ2hIUU10RWVUOEhfOHV0Ykh3ZF9MNGE1TWJUSzN2Ukt4Wi1FbGpWX0VPTWp1NzNweUd3Y3YzcDgydTFjLTBZMkk4NjJ4YUNkb21mUTY2bjJFOEJyYkhoUmR0SUpUTlBQQ0lHUDB6N05LTVl3VnJtRVBlSjRvU2VZcTktUVQ4b0ZKczBUY2VBZzBFNk5sQVlBam9tZkRmXzJkQlFaQkZLcXRDa2xEeW5adnhjQmJPd0Z4OENWN2Z4TUJrWF9EV2FnNVRCOUVZdVE?oc=5", "source_name": "PR Newswire", "published_at": "2025-08-08T07:00:00+00:00", "published_display": "08 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 61, "sentiment_summary": {"positive": 14, "negative": 1, "neutral": 46, "score": 55, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 22.9, "count": 41}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 0.89, "latest_week": "2026-07-10", "one_week_move": -1.3, "four_week_move": 10.5, "twelve_week_move": -20.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.172346, "market_dynamics_buy_signal": false, "relative_strength": -26.343491, "fair_value_gap": -19.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 36.2644, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.3% over one week, +10.5% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 6}, {"label": "simplywall.st", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "Moomoo", "count": 3}, {"label": "GuruFocus", "count": 2}, {"label": "ChartMill", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 41}, {"label": "Earnings", "count": 11}, {"label": "Regulatory and legal", "count": 4}, {"label": "Analyst action", "count": 3}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.3% over one week, +10.5% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer"}], "updated_at": "2026-07-16T08:14:16.167172+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}